112 related articles for article (PubMed ID: 24215052)
1. Langerhans cell sarcoma of the nasopharynx: a rare case.
Keklik M; Sivgin S; Kontas O; Abdulrezzak U; Kaynar L; Cetin M
Scott Med J; 2013 Nov; 58(4):e17-20. PubMed ID: 24215052
[TBL] [Abstract][Full Text] [Related]
2. ESHAP therapy effective in a patient with Langerhans cell sarcoma.
Yoshimi A; Kumano K; Motokura T; Takazawa Y; Oota S; Chiba S; Takahashi T; Fukayama M; Kurokawa M
Int J Hematol; 2008 Jun; 87(5):532-537. PubMed ID: 18415657
[TBL] [Abstract][Full Text] [Related]
3. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
4. [Interdigitating dendritic cell sarcoma of lower extremities resistant to high dose chemotherapy BEAM with peripheral blood stem cell transplantation].
Adam Z; Veselý K; Krejcí M; Pour L; Fakan F; Soumarová R; Neubauer J; Vanícek J; Cerný J; Kren L; Bolcák K; Smardová L; Hájek R; Mayer J
Vnitr Lek; 2009 Feb; 55(2):147-57. PubMed ID: 19348397
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of an elderly Langerhans cell sarcoma patient by EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) chemotherapy.
Matsukawa T; Suto K; Miyoshi H; Oshimi K; Ohshima K; Miyagishima T
J Clin Exp Hematop; 2018 Dec; 58(4):184-187. PubMed ID: 30305476
[No Abstract] [Full Text] [Related]
6. Etoposide, methylprednisolone, cytarabine and cisplatin successfully cytoreduces resistant myeloma patients and mobilizes them for transplant without adverse effects.
D'Sa S; Yong K; Kyriakou C; Bhattacharya S; Peggs KS; Foulkes B; Watts MJ; Ings SJ; Ardeshna KM; Goldstone AH; Williams CD
Br J Haematol; 2004 Jun; 125(6):756-65. PubMed ID: 15180865
[TBL] [Abstract][Full Text] [Related]
7. Langerhans cell sarcoma: a case report.
Valentín-Nogueras SM; Seijo-Montes R; Montalván-Miró E; Sánchez JL
J Cutan Pathol; 2013 Jul; 40(7):670-5. PubMed ID: 23590692
[TBL] [Abstract][Full Text] [Related]
8. Complexity of diagnosing and treating langerhans cell sarcoma: A case report.
Charfi M; Lajnaf M; Kallel F; Saguem I; Kassar O; Elloumi M
Tunis Med; 2023 Jul; 101(7):651-653. PubMed ID: 38445429
[TBL] [Abstract][Full Text] [Related]
9. Cutaneous Langerhans cell sarcoma relapsing systemically: Complete remission with the EPIG regimen.
Kwong YL
Ann Hematol; 2015 Apr; 94(4):697-9. PubMed ID: 25186787
[No Abstract] [Full Text] [Related]
10. [Successful treatment with total cranial irradiation for central nervous system involvement of Langerhans cell sarcoma during chemotherapy].
Nakagawa N; Yamazaki H; Yamashita T; Kondo Y; Nakao S
Rinsho Ketsueki; 2016 Jan; 57(1):25-30. PubMed ID: 26861100
[TBL] [Abstract][Full Text] [Related]
11. ESHAP chemotherapy regimen associated to lenalidomide induces complete isotopic remission in Hodgkin's lymphoma relapsing after autologous stem cell transplantation.
Tempescul A; Ianotto JC; Eveillard JR; Guillerm G; Berthou C
Ann Hematol; 2011 Aug; 90(8):971-3. PubMed ID: 21057951
[No Abstract] [Full Text] [Related]
12. Successful treatment of histiocytic sarcoma with cladribine and high-dose cytosine arabinoside in a child.
Iwabuchi H; Kawashima H; Umezu H; Takachi T; Imamura M; Saitoh A; Ogose A; Imai C
Int J Hematol; 2017 Aug; 106(2):299-303. PubMed ID: 28247189
[TBL] [Abstract][Full Text] [Related]
13. Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant.
Abidi MH; Tove I; Ibrahim RB; Maria D; Peres E
Am J Hematol; 2007 Oct; 82(10):932-3. PubMed ID: 17617785
[TBL] [Abstract][Full Text] [Related]
14. ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF.
Lee JL; Kim S; Kim SW; Kim EK; Kim SB; Kang YK; Lee J; Kim MW; Park CJ; Chi HS; Huh J; Kim SH; Suh C
Bone Marrow Transplant; 2005 Mar; 35(5):449-54. PubMed ID: 15654353
[TBL] [Abstract][Full Text] [Related]
15. Multi-centre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunction.
Bernard F; Thomas C; Bertrand Y; Munzer M; Landman Parker J; Ouache M; Colin VM; Perel Y; Chastagner P; Vermylen C; Donadieu J
Eur J Cancer; 2005 Nov; 41(17):2682-9. PubMed ID: 16291085
[TBL] [Abstract][Full Text] [Related]
16. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study.
Martín A; Conde E; Arnan M; Canales MA; Deben G; Sancho JM; Andreu R; Salar A; García-Sanchez P; Vázquez L; Nistal S; Requena MJ; Donato EM; González JA; León A; Ruiz C; Grande C; González-Barca E; Caballero MD;
Haematologica; 2008 Dec; 93(12):1829-36. PubMed ID: 18945747
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of salvage chemotherapy regimen ACES with ESHAP for refractory or relapsed malignant lymphoma].
Imataki O; Tamai Y; Kawakami K
Gan To Kagaku Ryoho; 2007 Oct; 34(10):1629-32. PubMed ID: 17940378
[TBL] [Abstract][Full Text] [Related]
18. Rituximab-ESHAP as a mobilization regimen for relapsed or refractory B-cell lymphomas: a comparison with ESHAP.
Kim MK; Kim S; Lee SS; Sym SJ; Lee DH; Kim SW; Jang S; Park CJ; Chi HS; Huh J; Suh C
Transfusion; 2007 Aug; 47(8):1447-54. PubMed ID: 17655589
[TBL] [Abstract][Full Text] [Related]
19. Fatal cisplatin overdose in the treatment of mediastinal lymphoma with the ESHAP regimen - analysis of the causes of the adverse drug event.
Jurek T; Rorat M; Dys P; Swiatek B
Onkologie; 2013; 36(1-2):49-52. PubMed ID: 23429332
[TBL] [Abstract][Full Text] [Related]
20. A case of an adult Langerhans cell sarcoma.
Ma X; Li W; Du J; Cai L; Zhang J
Int J Dermatol; 2016 Jan; 55(1):92-6. PubMed ID: 25312302
[No Abstract] [Full Text] [Related]
[Next] [New Search]
